Supportive and Palliative Care, Orlando Health Cancer Institute, Orlando, Florida, USA.
University of Central Florida College of Medicine, Orlando, Florida, USA.
J Palliat Med. 2024 Jan;27(1):31-38. doi: 10.1089/jpm.2023.0251. Epub 2023 Aug 8.
Despite widespread use of opioid therapy in outpatient palliative medicine, there is limited evidence supporting its efficacy and safety in the long term. We sought to improve overdose risk scores, maintain pain reduction, and preserve patient function in a cohort with severe chronic pain as we managed opioid therapy for a duration of four years in an outpatient palliative care clinic. Over four years, we provided ongoing goal-concordant outpatient palliative care, including opioid therapy, using quarterly clinical encounters for a patient cohort with chronic pain. The project took place in the outpatient palliative medicine clinic of a regional cancer center in Orlando, Florida (United States). The subjects were a cohort group who received palliative care during the time period between July 2018 and October 2022. Key metrics included treatment-related reduction in pain intensity, performance scores, and overall overdose risk scores. Secondary metrics included cohort demographics, average daily opioid use in morphine milligram equivalents and categorization of type of pain. In 97 patients, we observed a stable mean treatment-related reduction in pain intensity of 4.9 out of 10 points over four years. The cohort showed a 2-point (out of 100) improvement in performance scores and an 81-point (out of 999) reduction in mean overall overdose risk score. We present evidence that providing outpatient palliative care longitudinally over four years offered lasting treatment-related reductions in pain intensity, preservation of performance status, and reduction in overall overdose risk.
尽管阿片类药物疗法在门诊姑息治疗中广泛应用,但长期疗效和安全性的证据有限。我们旨在提高重度慢性疼痛患者的过量风险评分,维持疼痛缓解,并保持患者的功能,我们在一家门诊姑息治疗诊所管理阿片类药物治疗长达四年。在四年期间,我们通过每季度一次的临床随访,为慢性疼痛患者群体提供持续的、符合目标的门诊姑息治疗,包括阿片类药物治疗。该项目在佛罗里达州奥兰多的一家地区癌症中心的门诊姑息治疗诊所进行。研究对象为 2018 年 7 月至 2022 年 10 月期间接受姑息治疗的患者群体。主要指标包括与治疗相关的疼痛强度、表现评分和总体过量风险评分的降低。次要指标包括患者群体的人口统计学特征、平均每日吗啡当量的阿片类药物使用量以及疼痛类型的分类。在 97 名患者中,我们观察到四年内与治疗相关的疼痛强度平均稳定降低了 4.9 分。该队列的表现评分提高了 2 分(满分 100 分),总体过量风险评分平均降低了 81 分(满分 999 分)。我们提供的证据表明,四年的长期门诊姑息治疗可提供持久的与治疗相关的疼痛强度降低、保持表现状态和降低总体过量风险。